Sun Pharma Advanced Research Company Limited – Q4 FY26 Results

key financial highlights

• Revenue from Operations:
  • Revenue (Q4 FY26): ₹1,85,322 Lakh
    • QoQ Change: +21,831.60%
    • YoY Change: +6,715.08%
  • Previous Quarter (Q3 FY26): ₹845 Lakh
  • Previous Year (Q4 FY25): ₹2,719 Lakh
• Profit After Tax (PAT):
  • PAT (Q4 FY26): ₹1,76,134 Lakh
    • QoQ Change: Turnaround from loss
    • YoY Change: Turnaround from loss
  • Previous Quarter (Q3 FY26): -₹8,042 Lakh Loss
  • Previous Year (Q4 FY25): -₹5,977 Lakh Loss
• QoQ Performance:
  • Revenue Trend: Massive sequential revenue jump supported by milestone income recognition.
    
  • Profit Trend: Strong turnaround from losses to record quarterly profitability.

Margin Analysis

Drivers:

• Revenue growth significantly outpaced expense growth.
• Professional charges increased but remained manageable relative to income surge.
• Clinical trial and development expenses declined sequentially.
• Operating leverage improved materially.
• Finance costs increased due to higher borrowings.

Insight:

• The quarter reflected extraordinary margin expansion driven primarily by operating revenue recognition and strong operating leverage.

Earning quality check

Key Drivers:

• Profitability improved materially during Q4 FY26.
• Equity position strengthened sharply.
• Operating cash flow remained negative despite accounting profits.
• Financing inflows supported liquidity.
• Exceptional income contribution materially boosted earnings.

Interpretations:

• While reported earnings improved sharply, cash flow conversion remains weak due to the nature of the pharmaceutical research business and working capital movements.

balance sheet Analysis

• Total Assets: ₹2,17,086 lakh
• Total Liabilities: ₹83,204 lakh

Insight:

• The balance sheet strengthened considerably with a sharp increase in shareholders’ equity and reduction in accumulated losses.

key risks

• Dependence on milestone and licensing income
• Clinical trial uncertainty
• Regulatory approval risks
• High earnings volatility
• Weak operating cash flow generation
• Rising finance costs and borrowings

management strategy signals

Focus Area:

• Commercialization of research pipeline
• Specialty pharmaceutical innovation
• Licensing and partnership expansion
• R&D optimization
• Cost management

Financial metrics table

Quarterly Performance Context